Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation
Open Access
- 1 September 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (9) , 4969-4984
Abstract
Despite effective antiretroviral therapy, HIV-1–infected cells continue to produce viral antigens and induce chronic immune exhaustion. We propose to identify HIV-1–suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1–induced immune activation. Using a newly developed dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed HIV-1–infected individuals. We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets. Using differential expression analysis, gene set enrichment analysis, and exon-intron landscape analysis, we examined the impact of drug treatment on the cellular environment at a genome-wide level. We identified what we believe to be a new function of a JAK inhibitor, filgotinib, that suppresses HIV-1 splicing. First, filgotinib preferentially suppresses spliced HIV-1 RNA transcription. Second, filgotinib suppresses HIV-1–driven aberrant cancer-related gene expression at the integration site. Third, we found that filgotinib suppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing. Finally, we found that filgotinib treatment reduces the proliferation of HIV-1–infected cells. Overall, the combination of a drug screen and transcriptome analysis provides systematic understanding of cellular targets required for HIV-1 reactivation and drug candidates that may reduce HIV-1–related immune activation.Keywords
Funding Information
- W. W. Smith Charitable Trust (W. W. Smith AIDS Research Grant)
- Gilead Sciences (Gilead HIV Research Scholar Grant)
- Yale University (Yale Top Scholar)
- National Institute of Health (R01 AI141009,R61 DA047037,R21AI118402,P30AI094189,UM1AI126620,P50 AI150464,P30 AI027763,R24 AI067039,AI096109,A127966,R37 AI147868)
This publication has 113 references indexed in Scilit:
- Strategies to Block HIV Transcription: Focus on Small Molecule Tat InhibitorsBiology, 2012
- Reactivation of Latent HIV-1 by Inhibition of BRD4Cell Reports, 2012
- Immunologic Basis of Cardiovascular Disease in HIV-Infected AdultsThe Journal of Infectious Diseases, 2012
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Histone deacetylase inhibitors and HIV latencyCurrent Opinion in HIV and AIDS, 2011
- Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activationProceedings of the National Academy of Sciences, 2009
- The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylationGenes & Development, 2008
- Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of TherapyThe Journal of Infectious Diseases, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003